BiVictriX Interim results for the six months ended 30 June 2022
September 12th, 2022
Alderley Park, 12 September 2022 – BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, today announces its unaudited interim results for the six months ended 30 June 2022.
Related Stories
Head office
Copyright: BiVictriX Therapeutics plc 2023.
All Rights Reserved. Design & Development By Online Web Studio